Nancy M Dunbar1, Mark H Yazer2. 1. Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. 2. The Institute for Transfusion Medicine and the Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Use of universally ABO-compatible group AB plasma for trauma resuscitation can be challenging due to supply limitations. Many centers are now using group A plasma during the initial resuscitation of traumatically injured patients. This study was undertaken to evaluate the impact of this practice on mortality and hospital length of stay (LOS). STUDY DESIGN AND METHODS: Seventeen trauma centers using group A plasma in trauma patients of unknown ABO group participated in this study. Eligible patients were group A, B, and AB trauma patients who received at least 1 unit of group A plasma. Data collected included patient sex, age, mechanism of injury, Trauma Injury Severity Score (TRISS) probability of survival, and number of blood products transfused. The main outcome of this study was in-hospital mortality differences between group B and AB patients compared to group A patients. Data on early mortality (≤24 hr) and hospital LOS were also collected. RESULTS: There were 354 B and AB patients and 809 A patients. The two study groups were comparable in terms of age, sex, TRISS probability of survival, and total number of blood products transfused. The use of group A plasma during the initial resuscitation of traumatically injured patients of unknown ABO group was not associated with increased in-hospital mortality, early mortality, or hospital LOS for group B and AB patients compared to group A patients. CONCLUSION: These results support the practice of issuing thawed group A plasma for the initial resuscitation of trauma patients of unknown ABO group.
BACKGROUND: Use of universally ABO-compatible group AB plasma for trauma resuscitation can be challenging due to supply limitations. Many centers are now using group A plasma during the initial resuscitation of traumatically injuredpatients. This study was undertaken to evaluate the impact of this practice on mortality and hospital length of stay (LOS). STUDY DESIGN AND METHODS: Seventeen trauma centers using group A plasma in traumapatients of unknown ABO group participated in this study. Eligible patients were group A, B, and AB traumapatients who received at least 1 unit of group A plasma. Data collected included patient sex, age, mechanism of injury, Trauma Injury Severity Score (TRISS) probability of survival, and number of blood products transfused. The main outcome of this study was in-hospital mortality differences between group B and ABpatients compared to group A patients. Data on early mortality (≤24 hr) and hospital LOS were also collected. RESULTS: There were 354 B and ABpatients and 809 A patients. The two study groups were comparable in terms of age, sex, TRISS probability of survival, and total number of blood products transfused. The use of group A plasma during the initial resuscitation of traumatically injuredpatients of unknown ABO group was not associated with increased in-hospital mortality, early mortality, or hospital LOS for group B and ABpatients compared to group A patients. CONCLUSION: These results support the practice of issuing thawed group A plasma for the initial resuscitation of traumapatients of unknown ABO group.
Authors: Meghan Delaney; Oliver Karam; Lani Lieberman; Katherine Steffen; Jennifer A Muszynski; Ruchika Goel; Scot T Bateman; Robert I Parker; Marianne E Nellis; Kenneth E Remy Journal: Pediatr Crit Care Med Date: 2022-01-01 Impact factor: 3.971
Authors: Claudia S Cohn; Lise Estcourt; Brenda J Grossman; Monica B Pagano; Elizabeth S Allen; Evan M Bloch; Arturo Casadevall; Dana V Devine; Nancy M Dunbar; Farid Foroutan; Thomas J Gniadek; Ruchika Goel; Jed Gorlin; Michael J Joyner; Ryan A Metcalf; Jay S Raval; Todd W Rice; Beth H Shaz; Ralph R Vassallo; Jeffrey L Winters; Gregory Beaudoin; Aaron A R Tobian Journal: Transfusion Date: 2021-03-07 Impact factor: 3.337
Authors: Evan M Bloch; Aaron A R Tobian; Shmuel Shoham; Daniel F Hanley; Thomas J Gniadek; Edward R Cachay; Barry R Meisenberg; Kimberly Kafka; Christi Marshall; Sonya L Heath; Aarthi Shenoy; James H Paxton; Adam Levine; Donald Forthal; Yuriko Fukuta; Moises A Huaman; Alyssa Ziman; Jill Adamski; Jonathan Gerber; Daniel Cruser; Seble G Kassaye; Giselle S Mosnaim; Bela Patel; Ryan A Metcalf; Shweta Anjan; Ronald B Reisler; Anusha Yarava; Karen Lane; Nichol McBee; Amy Gawad; Jay S Raval; Martin Zand; Matthew Abinante; Patrick B Broderick; Arturo Casadevall; David Sullivan; Kelly A Gebo Journal: Transfusion Date: 2022-04-04 Impact factor: 3.337
Authors: Amory de Roulet; Jeffrey D Kerby; Jordan A Weinberg; Richard H Lewis; Jay P Hudgins; Ira A Shulman; Erin E Fox; John B Holcomb; Karen J Brasel; Eileen M Bulger; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Terence O'Keeffe; Sandro Rizoli; Thomas M Scalea; Martin A Schreiber; Kenji Inaba Journal: J Trauma Acute Care Surg Date: 2020-12 Impact factor: 3.697